Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Roundup of Articles Published in Recent Months

A Roundup of Articles Published in Recent Months BEST OF THE MONTH Janakiraman Subramanian, MD, MPH,*† Saiama Waqar, MD,*† Daniel Morgensztern, MD,‡ and Ramaswamy Govindan, MD*† patients with NSCLC (n  534). The study did not achieve Key Words: NSCLC, Lung cancer, Best papers. its primary end point of superior progression-free survival in (J Thorac Oncol. 2012;7: 626–628) patients receiving combination treatment compared with pemetrexed alone; HR 0.86 (95% confidence interval 0.68 – 1.08). Patients receiving vandetanib had higher incidence of hypertension, rash, and diarrhea. Results from these two VANDETANIB IN THE TREATMENT OF phase III trials show that vandetanib is not an option for unselected patients with advanced NSCLC. Identifying bio- RELAPSED/REFRACTORY NON-SMALL CELL markers that would predict for response would be the key to LUNG CANCER future development of vandetanib in NSCLC. Vandetanib is a small molecule tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor and FIBROBLAST GROWTH FACTOR RECEPTOR 1 epidermal growth factor receptor (EGFR). Two phase III AMPLIFICATION IN SQUAMOUS CELL LUNG trials evaluated vandetanib in the treatment of advanced non-small cell lung cancer (NSCLC); one compared single- CANCER agent vandetanib against erlotinib in the second- and third- Copy number analysis of 628 primary lung cancers and line setting and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Roundup of Articles Published in Recent Months

Govindan, Ramaswamy
Journal of Thoracic Oncology , Volume 7 (3) – Mar 1, 2012
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-roundup-of-articles-published-in-recent-months-3c7OmymMYg

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182436098
pmid
22334014
Publisher site
See Article on Publisher Site

Abstract

BEST OF THE MONTH Janakiraman Subramanian, MD, MPH,*† Saiama Waqar, MD,*† Daniel Morgensztern, MD,‡ and Ramaswamy Govindan, MD*† patients with NSCLC (n  534). The study did not achieve Key Words: NSCLC, Lung cancer, Best papers. its primary end point of superior progression-free survival in (J Thorac Oncol. 2012;7: 626–628) patients receiving combination treatment compared with pemetrexed alone; HR 0.86 (95% confidence interval 0.68 – 1.08). Patients receiving vandetanib had higher incidence of hypertension, rash, and diarrhea. Results from these two VANDETANIB IN THE TREATMENT OF phase III trials show that vandetanib is not an option for unselected patients with advanced NSCLC. Identifying bio- RELAPSED/REFRACTORY NON-SMALL CELL markers that would predict for response would be the key to LUNG CANCER future development of vandetanib in NSCLC. Vandetanib is a small molecule tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor and FIBROBLAST GROWTH FACTOR RECEPTOR 1 epidermal growth factor receptor (EGFR). Two phase III AMPLIFICATION IN SQUAMOUS CELL LUNG trials evaluated vandetanib in the treatment of advanced non-small cell lung cancer (NSCLC); one compared single- CANCER agent vandetanib against erlotinib in the second- and third- Copy number analysis of 628 primary lung cancers and line setting and

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2012

References

  • Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non small cell lung cancer
    Natale
  • Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial
    de Boer
  • Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
    Dutt
  • Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
    Weiss
  • FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR
    Bivona
  • A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
    Lynch
  • End-of-life care for lung cancer patients in the United States and Ontario
    Warren
  • Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group
    Auperin
  • Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214
    Gore
  • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis
    Sun
  • Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress
    Chute
  • Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial
    Spigel